New transplant strategy aims to save more lives by taming dangerous side effects

NCT ID NCT01349101

Summary

This study tested if giving the drug cyclophosphamide *after* a stem cell transplant, instead of before, could make transplants safer and more effective for people with blood cancers. It focused on patients who needed a transplant but did not have a perfectly matched sibling donor. The main goal was to see if this new timing helped the donor cells successfully take hold while reducing severe complications and early deaths.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGICAL MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Thomas Jefferson University

    Philadelphia, Pennsylvania, 19107, United States

Conditions

Explore the condition pages connected to this study.